Company intelligence / Profile preview
Remedy Plan Therapeutics
Gaithersburg, Maryland, United Statesremedyplan.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Currently conducting a Phase 1 clinical trial of RPT1G (first-in-class hyperbolic NAMPT inhibitor) in adult healthy volunteers. The trial will evaluate safety, pharmacokinetics, and pharmacodynamics in preparation for upcoming oncology trials in AML and MDS patients. Dosing was initiated in November 2024.
- Therapeutic areas
- OncologyImmunologyMetabolic Disorders
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Remedy Plan Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Remedy Plan Therapeutics.